Image: Shutterstock
Key Takeaways
Bristol Myers expands Sotyktu into PsA, strengthening its immunology portfolio and growth strategy.
Sotyktu faces rivalry from Amgen's Otezla and Novartis' Cosentyx in key markets.
Legacy drugs face generic hits, making pipeline progress and label expansions critical for Bristol Myers.
Bristol Myers (Free Report) recently secured a meaningful label expansion for Sotyktu, with the FDA approving the drug for adults with active psoriatic arthritis (PsA). The decision adds a second major indication beyond plaque psoriasis, strengthening the product’s long-term commercial profile and lifecycle potential.
From an investment standpoint, this approval introduces a differentiated, oral therapy into a large and competitive PsA market historically dominated by injectable biologics. Sotyktu’s position as the first TYK2 inhibitor approved for PsA could support uptake, particularly among patients and physicians seeking convenient, non-biologic options earlier in the treatment paradigm.
Strategically, the label expansion reinforces Bristol Myers’ immunology franchise and diversifies revenue streams beyond oncology. With psoriatic arthritis affecting a meaningful subset of psoriasis patients, Sotyktu now addresses both skin and joint manifestations, increasing its addressable market and cross-selling potential within existing dermatology and rheumatology channels.
However, commercial execution will be key. The PsA market is highly competitive, with entrenched biologics and oral agents already available.
Overall, the PsA approval represents a catalyst for Bristol Myers, enhancing Sotyktu’s growth outlook and supporting a broader shift toward immunology as a durable revenue pillar. The drug raked in sales of $291 million in 2025, up 19% from 2024. Sotyktu is also being evaluated for lupus (data is expected later in the year) and Sjogren’s Disease.
Meanwhile, Bristol Myers is working on the label expansion of its drugs to strengthen its growth portfolio, which primarily comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati, and others.
Schizophrenia drug Cobenfy is being evaluated for psychosis associated with Alzheimer's disease, for agitation in Alzheimer's Disease and Alzheimer's Disease cognition.
The successful development of all late-stage pipeline candidates and label expansion of approved drugs should be a significant boost for the company as its legacy portfolio continues to be adversely impacted by the continued generic impact on Revlimid, Pomalyst, Sprycel, and Abraxane.
Competition for Bristol Myers’ Sotyktu
Sotyktu faces stiff competition from Amgen’s (Free Report) Otezla in the psoriasis space. Amgen acquired global commercial rights to Otezla from Celgene (now part of Bristol-Myers). Amgen is also evaluating Otezla in additional indications.
Novartis’ (Free Report) blockbuster drug Cosentyx is approved for various conditions like hidradenitis suppurativa, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis, as well as several pediatric inflammatory disorders.
Cosentyx is a fully human monoclonal antibody that blocks interleukin-17A, a cytokine involved in inflammatory pathways underlying several immune-mediated diseases. It is one of the top drugs for the company. The drug generated $6.7 billion in revenues for Novartis in 2025, representing 8% growth from 2024.
Bristol Myers’ Price Performance, Valuation, & Estimates
Shares of Bristol Myers have lost 4.8% over the past year against the industry’s growth of 11.2%.
Image Source: Zacks Investment Research
From a valuation standpoint, Bristol Myers has been trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, the stock has been trading at 9.34x forward earnings, higher than its mean of 8.48x but lower than the large-cap pharma industry’s 16.92x.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 EPS has moved north to $6.26 from $6.15 in the past 30 days, while the consensus estimate for 2027 has increased to $6.09 from $5.94.
Image Source: Zacks Investment Research
Bristol Myers currently carries a Zacks Rank #3 (Hold). Additionally, Amgen and Novartis also maintain the same Zacks Rank #3 (Hold) rating at the moment.
Comments
Log in or sign up to join the conversation.